Close monitoring of medicine stocks proved particularly useful during the COVID-19 pandemic. The FAMHP managed to act proactively and find solutions in time. The monitoring was done manually, but is now automated using a new Stock Monitoring Tool.
News FAMHP
There are 701 result(s) found based on your search criteria
1-10 from 701 result(s)
Coronavirus: weekly overview of 6 May 2021 on adverse reactions of COVID-19 vaccines
Every Thursday, the FAMHP publishes a cumulative overview of the adverse reactions reported after administration of a COVID-19 vaccine in Belgium. By being fully transparent, the FAMHP wants to increase confidence in COVID-19 vaccines.
Coronavirus: weekly overview of 29 April 2021 on adverse reactions of COVID-19 vaccines
Every Thursday, the FAMHP publishes a cumulative overview of the adverse reactions reported after administration of a COVID-19 vaccine in Belgium. By being fully transparent, the FAMHP wants to increase confidence in COVID-19 vaccines.
Coronavirus: weekly update of 27 April 2021 on vaccine deliveries and information on vaccination equipment
To increase transparency on the deliveries of COVID-19 vaccines and vaccination equipment, the FAMHP publishes the number of doses delivered to Belgium, how many of these doses are allocated to each of the federated entities and the size of the emergency stock. Also, regular updates are published on the number of needles and syringes that have been ordered and received.
Coronavirus: weekly overview of 22 April 2021 on adverse reactions of COVID-19 vaccines
Every Thursday, the FAMHP publishes a cumulative overview of the adverse reactions reported after administration of a COVID-19 vaccine in Belgium. By being fully transparent, the FAMHP wants to increase confidence in COVID-19 vaccines.
Coronavirus: COVID-19 Vaccine Janssen: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets. EMA confirms overall benefit-risk remains positive
At its meeting of 20 April 2021, EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) concluded that a warning about unusual blood clots with low blood platelets should be added to the product information for COVID-19 Vaccine Janssen. PRAC also concluded that these events should be listed as very rare side effects of the vaccine.
Coronavirus: weekly update of 20 April 2021 on vaccine deliveries and information on vaccination equipment
To increase transparency on the deliveries of COVID-19 vaccines and vaccination equipment, the FAMHP publishes the number of doses delivered to Belgium, how many of these doses are allocated to each of the federated entities and the size of the emergency stock. Also, regular updates are published on the number of needles and syringes that have been ordered and received.
PRAC April 2021 – Conclusions and additional review on Vaxzevria (AstraZeneca’s COVID-19 vaccine), and new investigations on COVID-19 Vaccine Janssen
During its April 2021 meeting, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) concluded on very rare cases of unusual blood clots with low blood platelets reported with Vaxzevria (formerly COVID-19 Vaccine AstraZeneca) and started reviewing a safety signal of capillary leak syndrome in patients vaccinated Vaxzevria. Furthermore, the PRAC is also investigating thromboembolic events reported following vaccination with COVID-19 Vaccine Janssen.
Coronavirus: weekly overview of 15 April 2021 on adverse reactions of COVID-19 vaccines
Every Thursday, the FAMHP publishes a cumulative overview of the adverse reactions reported after administration of a COVID-19 vaccine in Belgium. By being fully transparent, the FAMHP wants to increase confidence in COVID-19 vaccines.
Coronavirus: weekly update of 13 April 2021 on vaccine deliveries and information on vaccination equipment
To increase transparency on the deliveries of COVID-19 vaccines and vaccination equipment, the FAMHP publishes the number of doses delivered to Belgium, how many of these doses are allocated to each of the federated entities and the size of the emergency stock. Also, regular updates are published on the number of needles and syringes that have been ordered and received.